Advertisement

Topics

Eisai Company To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab

20:00 EDT 4 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Eisai Company To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab

NEXT ARTICLE

More From BioPortfolio on "Eisai Company To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab"

Quick Search
Advertisement